Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate
among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common …

Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …

Pancreatic ductal adenocarcinoma (PDAC) is characterized by notorious resistance to
current therapies attributed to inherent tumor heterogeneity and highly desmoplastic and …

Pancreatic cancer is the seventh leading cause of death in developed countries and it still
has a poor prognosis despite intense research in the last 20 years. Immunotherapy is a …

Objectives Systemic inflammatory response and survival has not been evaluated as a
predictive factor of chemotherapy in metastatic pancreatic cancer. The aim of this study was …

Immunotherapeutic modalities are currently revolutionizing cancer treatment. In pancreatic
cancer, however, early clinical trials have been disappointing. The optimization of …

Pancreatic ductal adenocarcinoma (PDAC) is the second leading cause of cancer-related
deaths worldwide. Despite immune checkpoints based immunotherapy highlights a new …

Undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), a variant of pancreatic
ductal adenocarcinoma (PDAC), has a striking genetic similarity to PDAC but a significantly …

Abstract Background: Herpes Virus Entry Mediator (HVEM) is an important immune
checkpoint in cancer recognition. HVEM expressed on tumor cell membranes activates …

Immune cell infiltration has been identified as a prognostic biomarker in several cancers.
However, no immune based biomarker has yet been validated for use in pancreatic ductal …